# Doxecitine and Doxribtimine-Expanded Access

> **NCT06590493** · — · AVAILABLE · sponsor: **UCB BIOSCIENCES, Inc.**

## Conditions studied

- Thymine Kinase 2 Deficiency

## Interventions

- **DRUG:** doxecitine and doxribtimine

## Key facts

- **NCT ID:** NCT06590493
- **Lead sponsor:** UCB BIOSCIENCES, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06590493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06590493, "Doxecitine and Doxribtimine-Expanded Access". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06590493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*